Comparison of two multiplexed technologies for profiling >1,000 serum proteins that may associate with tumor burden [version 1; peer review: 2 approved, 1 approved with reservations]

Background: In this pilot study, we perform a preliminary comparison of two targeted multiplex proteomics technologies for discerning serum protein concentration changes that may correlate to tumor burden in ovarian cancer (OC) patients. Methods: Using the proximity extension assay (PEA) and Quantib...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Annie Ren, Ioannis Prassas, Vijithan Sugumar, Antoninus Soosaipillai, Marcus Bernardini, Eleftherios P Diamandis, Vathany Kulasingam
Formato:	article
Lenguaje:	EN
Publicado:	F1000 Research Ltd 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/045f91375fa54c209514b1ea178c2d6f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:045f91375fa54c209514b1ea178c2d6f
record_format	dspace
spelling	oai:doaj.org-article:045f91375fa54c209514b1ea178c2d6f2021-11-29T14:03:15ZComparison of two multiplexed technologies for profiling >1,000 serum proteins that may associate with tumor burden [version 1; peer review: 2 approved, 1 approved with reservations]2046-140210.12688/f1000research.53364.1https://doaj.org/article/045f91375fa54c209514b1ea178c2d6f2021-06-01T00:00:00Zhttps://f1000research.com/articles/10-509/v1https://doaj.org/toc/2046-1402Background: In this pilot study, we perform a preliminary comparison of two targeted multiplex proteomics technologies for discerning serum protein concentration changes that may correlate to tumor burden in ovarian cancer (OC) patients. Methods: Using the proximity extension assay (PEA) and Quantibody® Kiloplex Array (QKA), we measured >1,000 proteins in the pre-surgical and post-surgical serum from nine OC patients (N=18 samples). We expect that proteins that have decreased significantly in the post-surgical serum concentration may correlate to tumor burden in each patient. Duplicate sera from two healthy individuals were used as controls (N=4 samples). We employed in-house ELISAs to measure five proteins with large serum concentration changes in pre- and post-surgical sera, from four of the original nine patients and the two original controls. Results: Both platforms showed a weak correlation with clinical cancer antigen 125 (CA125) data. The two multiplexed platforms showed a significant correlation with each other for >400 overlapping proteins. PEA uncovered 15 proteins, while QKA revealed 11 proteins, with more than a two-fold post-surgical decrease in at least six of the nine patients. Validation using single enzyme-linked immunosorbent assays (ELISAs) showed at least a two-fold post-surgical decrease in serum concentration of the same patients, as indicated by the two multiplex assays. Conclusion: Both methods identified proteins that had significantly decreased in post-surgical serum concentration, as well as recognizing proteins that had been implicated in OC patients. Our findings from a limited sample size suggest that novel targeted proteomics platforms are promising tools for identifying candidate serological tumor-related proteins. However further studies are essential for the improvement of accuracy and avoidance of false results.Annie RenIoannis PrassasVijithan SugumarAntoninus SoosaipillaiMarcus BernardiniEleftherios P DiamandisVathany KulasingamF1000 Research LtdarticleMedicineRScienceQENF1000Research, Vol 10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Annie Ren Ioannis Prassas Vijithan Sugumar Antoninus Soosaipillai Marcus Bernardini Eleftherios P Diamandis Vathany Kulasingam Comparison of two multiplexed technologies for profiling >1,000 serum proteins that may associate with tumor burden [version 1; peer review: 2 approved, 1 approved with reservations]
description	Background: In this pilot study, we perform a preliminary comparison of two targeted multiplex proteomics technologies for discerning serum protein concentration changes that may correlate to tumor burden in ovarian cancer (OC) patients. Methods: Using the proximity extension assay (PEA) and Quantibody® Kiloplex Array (QKA), we measured >1,000 proteins in the pre-surgical and post-surgical serum from nine OC patients (N=18 samples). We expect that proteins that have decreased significantly in the post-surgical serum concentration may correlate to tumor burden in each patient. Duplicate sera from two healthy individuals were used as controls (N=4 samples). We employed in-house ELISAs to measure five proteins with large serum concentration changes in pre- and post-surgical sera, from four of the original nine patients and the two original controls. Results: Both platforms showed a weak correlation with clinical cancer antigen 125 (CA125) data. The two multiplexed platforms showed a significant correlation with each other for >400 overlapping proteins. PEA uncovered 15 proteins, while QKA revealed 11 proteins, with more than a two-fold post-surgical decrease in at least six of the nine patients. Validation using single enzyme-linked immunosorbent assays (ELISAs) showed at least a two-fold post-surgical decrease in serum concentration of the same patients, as indicated by the two multiplex assays. Conclusion: Both methods identified proteins that had significantly decreased in post-surgical serum concentration, as well as recognizing proteins that had been implicated in OC patients. Our findings from a limited sample size suggest that novel targeted proteomics platforms are promising tools for identifying candidate serological tumor-related proteins. However further studies are essential for the improvement of accuracy and avoidance of false results.
format	article
author	Annie Ren Ioannis Prassas Vijithan Sugumar Antoninus Soosaipillai Marcus Bernardini Eleftherios P Diamandis Vathany Kulasingam
author_facet	Annie Ren Ioannis Prassas Vijithan Sugumar Antoninus Soosaipillai Marcus Bernardini Eleftherios P Diamandis Vathany Kulasingam
author_sort	Annie Ren
title	Comparison of two multiplexed technologies for profiling >1,000 serum proteins that may associate with tumor burden [version 1; peer review: 2 approved, 1 approved with reservations]
title_short	Comparison of two multiplexed technologies for profiling >1,000 serum proteins that may associate with tumor burden [version 1; peer review: 2 approved, 1 approved with reservations]
title_full	Comparison of two multiplexed technologies for profiling >1,000 serum proteins that may associate with tumor burden [version 1; peer review: 2 approved, 1 approved with reservations]
title_fullStr	Comparison of two multiplexed technologies for profiling >1,000 serum proteins that may associate with tumor burden [version 1; peer review: 2 approved, 1 approved with reservations]
title_full_unstemmed	Comparison of two multiplexed technologies for profiling >1,000 serum proteins that may associate with tumor burden [version 1; peer review: 2 approved, 1 approved with reservations]
title_sort	comparison of two multiplexed technologies for profiling >1,000 serum proteins that may associate with tumor burden [version 1; peer review: 2 approved, 1 approved with reservations]
publisher	F1000 Research Ltd
publishDate	2021
url	https://doaj.org/article/045f91375fa54c209514b1ea178c2d6f
work_keys_str_mv	AT annieren comparisonoftwomultiplexedtechnologiesforprofiling1000serumproteinsthatmayassociatewithtumorburdenversion1peerreview2approved1approvedwithreservations AT ioannisprassas comparisonoftwomultiplexedtechnologiesforprofiling1000serumproteinsthatmayassociatewithtumorburdenversion1peerreview2approved1approvedwithreservations AT vijithansugumar comparisonoftwomultiplexedtechnologiesforprofiling1000serumproteinsthatmayassociatewithtumorburdenversion1peerreview2approved1approvedwithreservations AT antoninussoosaipillai comparisonoftwomultiplexedtechnologiesforprofiling1000serumproteinsthatmayassociatewithtumorburdenversion1peerreview2approved1approvedwithreservations AT marcusbernardini comparisonoftwomultiplexedtechnologiesforprofiling1000serumproteinsthatmayassociatewithtumorburdenversion1peerreview2approved1approvedwithreservations AT eleftheriospdiamandis comparisonoftwomultiplexedtechnologiesforprofiling1000serumproteinsthatmayassociatewithtumorburdenversion1peerreview2approved1approvedwithreservations AT vathanykulasingam comparisonoftwomultiplexedtechnologiesforprofiling1000serumproteinsthatmayassociatewithtumorburdenversion1peerreview2approved1approvedwithreservations
_version_	1718407263964626944

Comparison of two multiplexed technologies for profiling >1,000 serum proteins that may associate with tumor burden [version 1; peer review: 2 approved, 1 approved with reservations]

Ejemplares similares